Have you seen the final trial design? It’s just one cohort. The 2L setting was eliminated because of uptake of Trodelvy in that setting. The trial is overenrolled and seems adequately powered to me. There wasn’t a material difference in 1L vs 2L efficacy in the P2. It was numerically lower but very small numbers. The bigger variable is the larger PDL (-) population in the P3
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.